Eli Lilly expects Medicare to extend GLP-1 weight-loss coverage

8 articles · Updated · The Wall Street Journal · May 1

Chief executive David Ricks said coverage should begin in July, continue through 2027 and likely be pushed into 2028 if the drugs are used at scale.
He said broader use among seniors could deliver population-level health improvements within 18 months and help make obesity care a standard preventive treatment for comorbidities.
The comments come as Lilly's GLP-1 business keeps expanding, with first-quarter sales of Mounjaro more than doubling to $8.66 billion and Zepbound rising 80% to $4.16 billion.

With Foundayo's slower-than-expected launch, can Eli Lilly maintain its dominance as the GLP-1 market rapidly evolves and new competitors emerge?

Will Medicare's temporary Bridge program for obesity drugs become a turning point in U.S. healthcare policy, or is broader coverage still years away?